{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:23:13Z","timestamp":1769066593097,"version":"3.49.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1097\/md.0000000000007147","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T15:55:45Z","timestamp":1497455745000},"page":"e7147","source":"Crossref","is-referenced-by-count":49,"title":["Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors"],"prefix":"10.1097","volume":"96","author":[{"given":"Fabian T.","family":"Camacho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor E.","family":"Alcal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surbhi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger T.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Balkrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-30-20210226","first-page":"541","article-title":"Adjuvant endocrine therapy for breast cancer","volume":"26","author":"Rao","year":"2012","journal-title":"Oncology"},{"key":"R2-30-20210226","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.","volume":"378","year":"2011","journal-title":"Lancet"},{"key":"R3-30-20210226","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R4-30-20210226","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-30-20210226","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10549-014-2957-z","article-title":"Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer","volume":"145","author":"Reeder-Hayes","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"R6-30-20210226","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-007-9675-8","article-title":"Parity and disparity in first course treatment of invasive breast cancer","volume":"109","author":"Lund","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"R7-30-20210226","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10549-011-1762-1","article-title":"Racial\/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer","volume":"131","author":"Livaudais","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"R8-30-20210226","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jnci\/94.5.334","article-title":"Racial and ethnic disparities in the receipt of cancer treatment","volume":"94","author":"Shavers","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R9-30-20210226","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10549-013-2499-9","article-title":"Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer","volume":"138","author":"Friese","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"R10-30-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-016-0732-1","article-title":"Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D","volume":"33","author":"Farias","year":"2016","journal-title":"Med Oncol"},{"key":"R11-30-20210226","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-016-3803-2","article-title":"Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer","volume":"157","author":"Felder","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"R12-30-20210226","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R13-30-20210226","doi-asserted-by":"crossref","first-page":"e1071","DOI":"10.1097\/MD.0000000000001071","article-title":"Adjuvant therapy use among Appalachian breast cancer survivors","volume":"94","author":"Tan","year":"2015","journal-title":"Medicine (Baltimore"},{"key":"R14-30-20210226","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ygyno.2015.04.025","article-title":"Geographic access to gynecologic cancer care in the United States","volume":"138","author":"Shalowitz","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R15-30-20210226","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/DCR.0000000000000173","article-title":"Does patient rurality predict quality colon cancer care?: a population-based study","volume":"58","author":"Chow","year":"2015","journal-title":"Dis Colon Rectum"},{"key":"R16-30-20210226","first-page":"13","article-title":"Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases","volume":"1","author":"Leslie","year":"2008","journal-title":"Pharm Progr"},{"key":"R17-30-20210226","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11096-013-9833-5","article-title":"Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer","volume":"36","author":"Ayres","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"R18-30-20210226","doi-asserted-by":"crossref","first-page":"499","DOI":"10.18553\/jmcp.2000.6.6.499","article-title":"Evaluating medication adherence: which measure is right for your program?","volume":"6","author":"Fairman","year":"2000","journal-title":"J Manag Care Pharm"},{"key":"R21-30-20210226","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2105\/AJPH.93.7.1137","article-title":"Area deprivation and widening inequalities in US mortality, 1969\u20131998","volume":"93","author":"Singh","year":"2003","journal-title":"Am J Public Health"},{"key":"R24-30-20210226","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R25-30-20210226","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"R26-30-20210226","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00038-008-7068-3","article-title":"When to use the odds ratio or the relative risk?","volume":"53","author":"Schmidt","year":"2008","journal-title":"Int J Public Health"},{"key":"R27-30-20210226","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ije\/dyu029","article-title":"Estimating predicted probabilities from logistic regression: different methods correspond to different target populations","volume":"43","author":"Muller","year":"2014","journal-title":"Int J Epidemiol"},{"key":"R28-30-20210226","first-page":"922","article-title":"Vital signs: racial disparities in breast cancer severityUnited States, 2005-2009.","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R30-30-20210226","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/cncr.20671","article-title":"Racial differences in knowledge, attitudes, and cancer screening practices among a triracial rural population","volume":"101","author":"Paskett","year":"2004","journal-title":"Cancer"},{"key":"R31-30-20210226","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.2008.17.9234","article-title":"Trends in racial and age disparities in definitive local therapy of early-stage breast cancer","volume":"27","author":"Freedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R32-30-20210226","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/theoncologist.2013-0243","article-title":"Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research","volume":"18","author":"Wheeler","year":"2013","journal-title":"Oncologist"},{"key":"R33-30-20210226","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12032-015-0599-6","article-title":"Socio-demographic and geographic variations in the utilization of hormone therapy in older women with breast cancer after Medicare Part-D coverage","volume":"32","author":"Wang","year":"2015","journal-title":"Med Oncol"},{"key":"R34-30-20210226","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/2193-1801-2-356","article-title":"Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer","volume":"2","author":"Bhatta","year":"2013","journal-title":"Springerplus"},{"key":"R35-30-20210226","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2105\/AJPH.2014.302490","article-title":"Racial\/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review","volume":"105","author":"Roberts","year":"2015","journal-title":"Am J Public Health"},{"key":"R36-30-20210226","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.5600\/mmrr.001.04.a04","article-title":"Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D","volume":"1","author":"Riley","year":"2011","journal-title":"Medicare Medicaid Res Rev"},{"key":"R37-30-20210226","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10549-011-1703-z","article-title":"Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer","volume":"130","author":"Nekhlyudov","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R38-30-20210226","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J Clin Oncol"},{"key":"R39-30-20210226","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","article-title":"Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer","volume":"26","author":"Partridge","year":"2008","journal-title":"J Clin Oncol"},{"key":"R40-30-20210226","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1188\/14.ONF.274-285","article-title":"Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer","volume":"41","author":"Bender","year":"2014","journal-title":"Oncol Nurs Forum"},{"key":"R41-30-20210226","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1476-072X-11-48","article-title":"Medication deserts: survey of neighborhood disparities in availability of prescription medications","volume":"11","author":"Amstislavski","year":"2012","journal-title":"Int J Health Geogr"},{"key":"R42-30-20210226","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.sapharm.2016.08.004","article-title":"Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer","volume":"13","author":"Tan","year":"2016","journal-title":"Res Social Adm Pharm"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:51:54Z","timestamp":1620960714000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201706160-00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":37,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007147","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}